Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab
Authors:
- Janet S. LeeJLJanet S. Lee
- Jianmei WangJWJianmei Wang
- Mitchell MartinMMMitchell Martin
- Soren GermerSGSoren Germer
- Andrew KenwrightAKAndrew Kenwright
- Ryma BenayedRBRyma Benayed
- Olivia SpleissOSOlivia Spleiss
- Adam PlattAPAdam Platt
- Robert PilsonRPRobert Pilson
- Andrew HemmingsAHAndrew Hemmings
- Michael E. WeinblattMWMichael E. Weinblatt
- Neil KaplowitzNKNeil Kaplowitz
- 1 July 2011
- journal article
- Published by Wolters Kluwer Health in Pharmacogenetics and Genomics
- Vol. 21 (7) , 365-374
Abstract
Tocilizumab, a monoclonal antibody to interleukin-6 receptor, was recently approved for the treatment of moderate-to-severe rheumatoid arthritis. Two patients during clinical development met laboratory, but not clinical, criteria for Hy's law with bilirubin elevations suspected as a result of genetic variation in uridine diphosphoglucose glucuronosyltransferase (UGT1A1) typical of Gilbert syndrome. Genotyping of the two cases potentially meeting with Hy's law was performed using commercially available procedures. UGT1A1 single nucleotide polymorphism data were extracted from a genome-wide array database for 1187 patients from tocilizumab trials, and associations of UGT1A1 genotypes with bilirubin elevations were analyzed using logistic regression for associations with baseline and change from baseline in bilirubin levels as continuous variables. Bilirubin elevations were not associated with clinical adverse events. Both patients potentially meeting Hy's law carry homozygous UGT1A1*28 alleles and UGT1A1*60 alleles. UGT1A1*28 and three additional single nucleotide polymorphisms showed odds ratios greater than 25 for associations with elevated bilirubin. The presence of rs6742078 accounted for 32% of the total variance in bilirubin (P=2.2×10). Bilirubin increases occurring with tocilizumab appear to be related to anti-inflammatory effects extending to the liver. Thus, in the absence of other signs of hepatic dysfunction, bilirubin elevations after treatment with tocilizumab have a high probability of association with UGT1A1 polymorphism, which should alleviate concerns of serious hepatotoxicity. Our results underscore the value of genotyping in the clinical trial setting to avoid misinterpretations that could lead to terminating development of a promising new agent.Keywords
This publication has 21 references indexed in Scilit:
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION studyAnnals of the Rheumatic Diseases, 2010
- Targeting IL-6 in the treatment of inflammatory and autoimmune diseasesExpert Opinion on Investigational Drugs, 2009
- Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjectsJournal of Human Genetics, 2009
- TocilizumabNature Reviews Drug Discovery, 2009
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trialAnnals of the Rheumatic Diseases, 2008
- Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy studyArthritis & Rheumatism, 2008
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Drug-Induced Liver InjuryDrug Safety, 2007
- Molecular diagnosis of a familial nonhemolytic hyperbilirubinemia (Gilbert’s syndrome) in healthy subjectsHepatology, 2000
- Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: Correlation of genotype to phenotypeHuman Mutation, 2000